Danaher Corporation (DHR) Reports Q1 Adjusted EPS Beat

On April 21, 2026, Danaher Corporation (NYSE:DHR) reported Q1 adjusted EPS of $2.06, supra the $1.94 consensus, with gross of $6B successful enactment with expectations. Rainer Blair said the institution “executed good successful the archetypal quarter,” citing astir 10% adjusted EPS growth, continued betterment successful Bioprocessing, and better-than-expected show successful Life Sciences, which helped offset a lighter respiratory play astatine Cepheid. Rainer Blair besides pointed to the planned acquisition of Masimo Corporation, noting opportunities to amended show done standard and operating capabilities.

The institution raised its FY26 adjusted EPS outlook to $8.35–$8.55 from $8.35–$8.50, compared with a $8.40 consensus, and reiterated expectations for non-GAAP halfway gross maturation of 3% to 6% year-over-year. Danaher besides highlighted its equilibrium expanse and escaped currency travel procreation arsenic supporting further superior deployment.

Following the results, Jefferies expert Tycho Peterson raised the terms people connected Danaher Corporation (NYSE:DHR) to $245 from $240 and maintained a Buy standing aft what was described arsenic a “solid” Q1, noting easing headwinds, emerging maturation signals, and valuation that is “not demanding.”

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, research, and concern products and services globally.

While we admit the imaginable of DHR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.